phase 1_completion
saveGSK plc — bepirovirsen sodium (Phase I Trial Completion)
community read0 votes
Therapy area: Infectious Disease. Indication: Hepatitis B
Data sources
globaldata
Found something off?
same company · ±60 days · 6
- patent expiry(abacavir sulfate + dolutegravir sodium + lamivudine): GSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))Apr 28, 2026
- patent expirycabotegravir sodium: GSK plc — cabotegravir sodium (Constraining Patent Expiry (US))Apr 28, 2026
- drug expirycabotegravir sodium: GSK plc — cabotegravir sodium (Drug Expiry (US))Apr 28, 2026
- patent expirydolutegravir sodium: GSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))Apr 28, 2026
- earningsGSK plc earningsApr 29, 2026
- phase 2 initiationdostarlimab: GSK plc — dostarlimab (Phase II Trial Initiation)Apr 25, 2026
comments(0)
5-min edit window · permanent after that